Difference between revisions of "Part:BBa K1123005:Experience"

Latest revision as of 18:05, 17 October 2018

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K1123005

A characterization and usage example of this part can be found on its main page BBa_K1123005

User Reviews

UNIQf03f14f877be6994-partinfo-00000000-QINU UNIQf03f14f877be6994-partinfo-00000001-QINU

@@ Line 6: / Line 6: @@
 ===Applications of BBa_K1123005===
 A characterization and usage example of this part can be found on its main page [[Part:BBa_K1123005 | BBa_K1123005]]
-This characterization is provided by TJU_China 2018 IGEM team. We firstly amplified the eGFP fragment from BBa_K1123005(iGEM13_TU-Eindhoven) by PCR.
-https://static.igem.org/mediawiki/2018/e/e5/T--TJU_China--3-9.png
-Figure 1. Amplification of eGFP fragment (BBa_K1123005) by PCR. Lane M, marker. Lane 1, 25ng eGFP fragment. Lane 2, 50ng. Lane 3, 100ng. Lane 4, 150ng. Lane 5, 200ng.
-Since this fragment contains the cleavage site of our sgRNA, we used it to test the in vitro cleavage activity of our CRISPR/Cas9 system. Please notice that our cleavage site was not so suitable for this fragment since it was designed for plasmid cutting(fragment of 720bp is cut into fragments of about 80bp and 640bp)
-https://static.igem.org/mediawiki/2018/c/ce/T--TJU_China--3-10.png
-Figure 2. In vitro cleavage of eGFP fragment. Lane M, marker. Lane 1, eGFP fragment. Lane 2-3, sgRNA:Cas9:DNA=10:10:1. Lane 4-5, sgRNA:Cas9:DNA=10:20:1. Lane 6-7,  sgRNA:Cas9:DNA=20:20:1.
 ===User Reviews===